Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluviral (2013-2014) Immunogenicity and Safety in Adults
NCT01878825Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2013
- Primary completion
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated) in influenza (2 arms), sponsored by GSK. Primary endpoints: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers at Day 21, Number of Seroconverted Subjects for HI Antibodies at Day 21 and 2 more. Started Jul 2013; status: completed.
02
Drugs
influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01878825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01878825.